Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
- 1 July 2025
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (9) , 101997
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi studyeClinicalMedicine, 2024
- Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysisCancer, 2022
- Antibody drug conjugate: the “biological missile” for targeted cancer therapySignal Transduction and Targeted Therapy, 2022
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2021
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer, 2020
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugatesPharmacology & Therapeutics, 2019
- A Review of Clinical Radioprotection and Chemoprotection for Oral MucositisTranslational Oncology, 2018
- Innovative intraoral cooling device better tolerated and equally effective as ice coolingCancer Chemotherapy and Pharmacology, 2017
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersBioconjugate Chemistry, 2015
- The pathobiology of mucositisNature Reviews Cancer, 2004